Payment overview · 2025
General Payments
$2,352.78
120 reported records · 24 companies
Healthcare provider profile · identity verified
John Harris, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BELLEVUE, NE · NPI 1043360043
Verified facts
What the public records show
CMS Open Payments records show John Harris, M.D. received $2,352.78 in general payments during 2025 across 120 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 580 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $471.21 | 20.0% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $378.58 | 16.1% | 28 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $225.98 | 9.6% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $212.28 | 9.0% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $157.10 | 6.7% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.55 | 6.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.84 | 5.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.27 | 4.8% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.16 | 4.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.80 | 2.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.84 | 2.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.63 | 1.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $36.94 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.35 | 1.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.45 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.92 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.25 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.88 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.78 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.68 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.38 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.89 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.92 | 0.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,352.78 | 120 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $269.67 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $226.34 | 19 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $200.91 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $189.45 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $167.02 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.55 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $139.54 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $137.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.97 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $94.16 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.52 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.80 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.96 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.84 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.00 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.44 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.92 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 580 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
93 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
580 | 75 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 895 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 182 |
| Lisinopril | Lisinopril | 679 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 129 |
| Eliquis | Apixaban | 580 | 75 |
| Gabapentin | Gabapentin | 500 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 493 | 113 |
| Omeprazole | Omeprazole | 471 | 114 |
| Furosemide | Furosemide | 448 | 99 |
| Meloxicam | Meloxicam | 376 | 90 |
| Losartan Potassium | Losartan Potassium | 362 | 97 |
| Potassium Chloride | Potassium Chloride | 343 | 76 |
| Simvastatin | Simvastatin | 340 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 72 |
| Montelukast Sodium | Montelukast Sodium | 284 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 74 |
| Metformin Hcl | Metformin Hcl | 251 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 51 |
| Sertraline Hcl | Sertraline Hcl | 229 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 54 |
| Alprazolam | Alprazolam | 215 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 208 | 21 |
| Tramadol Hcl | Tramadol Hcl | 184 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 38 |
| Buspirone Hcl | Buspirone Hcl | 157 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 56 |
| Mirtazapine | Mirtazapine | 148 | 25 |
| Myrbetriq | Mirabegron | 135 | 15 |
| Carvedilol | Carvedilol | 132 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 47 |
| Donepezil Hcl | Donepezil Hcl | 121 | 22 |
| Celecoxib | Celecoxib | 115 | 23 |
| Trazodone Hcl | Trazodone Hcl | 114 | 25 |
| Ezetimibe | Ezetimibe | 106 | 25 |
| Allopurinol | Allopurinol | 103 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 21 |
| Atenolol | Atenolol | 98 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 26 |
| Metformin Hcl Er | Metformin Hcl | 97 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 19 |
| Entresto | Sacubitril/Valsartan | 93 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 90 | 26 |
| Latanoprost | Latanoprost | 87 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 20 |
| Levetiracetam | Levetiracetam | 84 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 11 |
| Fenofibrate | Fenofibrate | 79 | 18 |
| Xarelto | Rivaroxaban | 79 | 11 |
| Jardiance | Empagliflozin | 78 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 15 |
| Clonazepam | Clonazepam | 77 | 14 |
| Prednisone | Prednisone | 76 | 27 |
| Spironolactone | Spironolactone | 76 | 22 |
| Finasteride | Finasteride | 75 | 17 |
| Memantine Hcl | Memantine Hcl | 75 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 72 | 23 |
| Glimepiride | Glimepiride | 68 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 14 |
| Torsemide | Torsemide | 63 | 15 |
| Azithromycin | Azithromycin | 61 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 44 |
| Famotidine | Famotidine | 60 | 11 |
| Lorazepam | Lorazepam | 58 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Butorphanol Tartrate | Butorphanol Tartrate | 53 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 24 |
| Glipizide | Glipizide | 49 | 14 |
| Ibuprofen | Ibuprofen | 48 | 13 |
| Meclizine Hcl | Meclizine Hcl | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 11 |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 47 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Cephalexin | Cephalexin | 42 | 30 |
| Glipizide Er | Glipizide | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 13 |
| Ondansetron Odt | Ondansetron | 31 | 18 |
| Ozempic | Semaglutide | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 15 |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 14 |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Betaseron | Interferon Beta-1b | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,352.78 · 120 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, WATCHMAN Access System, Wegovy, ZENPEP, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error